Back to top

gene-editing: Archive

Ekta Bagri

Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait?

While Prime Medicine (PRME) exhibits potential with its encouraging pipeline progress, the current cash position warrants caution. We advise a wait-and-watch approach at current levels.

VRTXPositive Net Change PRMENegative Net Change CRSPNegative Net Change

Zacks Equity Research

Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies

Editas (EDIT) reports positive new safety and efficacy data from the RUBY and EdiTHAL studies evaluating its investigational gene therapy, reni-cel, for SCD and TDT, respectively.

VRTXPositive Net Change EDITNegative Net Change CRSPNegative Net Change ALXONegative Net Change